Biomarkers Market worth $78.1 billion in 2026 - Report by MarketsandMarkets™
Chicago, June 30, 2022 (GLOBE NEWSWIRE) -- According to the new market research report, the "Biomarkers Market *by Product (Consumable, Service), Type (Safety, Efficacy, Validation), Disease (Cancer (Solid & Liquid Biopsy), Neurological), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine) - Global Forecast to 2026"*, is expected to reach USD 78.1 billion in 2026 from USD 43.1 billion in 2021 at a CARG of 12.6%.
Browse in-depth TOC on "*Biomarkers Market*"
244- Tables
40- Figures
238 - Pages
*Download PDF Brochure:* https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43The Growth in the biomarkers market is mainly driven by factors such as the growing importance of companion diagnostics, increasing prevalence of cancer worldwide, increasing funds & grants for biomarker research, and continuous product innovations.
By product & service, the biomarker market is segmented into consumables, services, and software. In 2020, the consumables segment accounted for the fastest-growing segment of the global market. The growth of this segment can primarily be attributed to the increasing use of kit-based products for biomarker testing and the repeated purchase of consumables.
Based on application, the biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. In 2020, the diagnostics segment accounted for the fastest-growing segment of the market. The use of biomarkers for the diagnosis of multiple diseases, including cancer, infectious diseases, cardiovascular disorders, and neurological disorders, is on the rise. The increasing use of biomarkers is a major factor that drives the growth of the diagnostics segment of the market.
*Request Sample Pages:* https://www.marketsandmarkets.com/requestsampleNew.asp?id=43Based on disease indication, the biomarkers market is segmented into cancer, infectious diseases, neurological disorders, immunological disorders, cardiovascular disorders, and other disease indications. In 2020, the infectious diseases segment accounted for the largest share of the market. The large share of this segment can be attributed to the growing prevalence of infectious diseases, coupled with the outbreak of the COVID-19 pandemic.
Based on type, the biomarkers market is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. In 2020, the efficacy biomarkers segment accounted for the largest share of the global market. The large share of this segment can be attributed to the ability of these biomarkers to evaluate the therapeutic efficacy of drug products.
*Speak to Analyst:* https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=43*Geographical Growth Scenario:*
The biomarkers market in the Asia Pacific region is projected to register the highest growth during the forecast period. The growth of this segment is primarily due to the increasing use of biomarkers for diagnostic purposes, the growing prevalence of chronic diseases, favorable government initiatives, and the growing focus on genomic & proteomic research projects.
*Key Players in Biomarkers Market:*
· F. Hoffmann-La Roche Ltd. (Switzerland),
· Thermo Fisher Scientific Inc. (US),
· Abbott Laboratories (US),
· QIAGEN N.V. (Netherlands),
· PerkinElmer, Inc. (US),
· Merck KGaA (Germany),
· Bio-Rad Laboratories, Inc. (US),
· Enzo Biochem, Inc. (US),
· Charles River Laboratories International, Inc. (US), and
· Eurofins Scientific (Luxembourg).
*Browse Adjacent Markets*: Biotechnology Market Research Reports & Consulting
*Browse Related Reports:*
*Cancer Biomarkers Market* by Type (Protein, Genetic), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnostics, R&D, Prognostics), Region - Global Forecast to 2026
https://www.marketsandmarkets.com/Market-Reports/oncology-biomarkers-202.html*Biomarker Technologies Market* by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) - Global Forecast to 2022
https://www.marketsandmarkets.com/Market-Reports/biomarker-technologies-market-190358765.htmlCONTACT: About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com